Phase II Pilot Study of Vemurafenib in Patients WithMetastatic BRAF-Mutated ColorectalCancer. J Clin Oncol 2015; 33:4032–4038 3. Julien Taieb etal. Exploring the best treatment options for BRAF-mutant metastaticcolon cancer. ...
3. Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer.J. Clin. Oncol.33, 4032–4038 (2015). 4. Pai, R. et al. Prostaglandin E2 transactivates EGF...
这周的文献选自《Cell Reports》的“NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor”在这项研究中,旨在揭示控制NFE2L3调节和功能的通路网络。 … labex PD-1治疗结直肠癌的正确打开方式 PD-1免疫治疗药物的上市为晚期已经转移的结直肠癌患者带来了曙光,可同是结直肠癌...
Colon cancerEpithelial to mesenchymal transitionNon-V600E BRAF mutationRegorafenibBackground: Non-V600E BRAF mutated colorectal cancer (CRC) is a rare disease entity with specific clinical features. These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation ...
Piringer G, Decker J, Trommet V, et al. Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review[J]. Frontiers in ...
GENETICS of colon cancerLYNCH syndrome IIONCOGENESMICROSATELLITE repeatsMETHYLATIONThe aim of the study was to detect mutations of BRAF oncogene in colorectal cancer and to use this information to identify Lynch syndrome patients. Consecutive cases of primary colorectal cancer ( n = 137) were analyzed...
1. Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. doi:10.1200/JCO.2015.63.24972. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature...
Predictive and prognostic roles of BRAF mutation in stage Ⅲ colon cancer: results from intergroup trial CALGB89803 [J]. Clin Cancer Res, 2012, 18(3):890-900. [15] Pai R K, Jayachandran P, Koong A C, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an ...
Finally,BRAF-mt patients should not be considered as having a unique biology. In fact, Barras et al.25have even recently described, from a series of 218BRAF-mt patients with colon cancer, two distinct subtypes of patient, independent of their gender, primary tumour location, mismatch repair (...
17. Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N EnglJ Med. 2010;363(9):809-81. 18. Kopetz S, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal...